Pennant posts Q4 revenue of USD 289.3 million, up 53.2%

Reuters02-26
Pennant posts Q4 revenue of USD 289.3 million, up 53.2%

Pennant reported FY 2025 GAAP diluted EPS of USD 0.84 and Q4 GAAP diluted EPS of USD 0.24, with adjusted diluted EPS of USD 1.18 for FY 2025 and USD 0.34 for Q4. FY 2025 revenue was USD 947.7 million (up 36.3%) and Q4 revenue was USD 289.3 million (up 53.2%). FY net income attributable to shareholders was USD 29.6 million (up 31.1%) and Q4 net income attributable to shareholders was USD 8.6 million (up 50.0%), while FY adjusted net income was USD 41.6 million (up 38.9%) and Q4 adjusted net income was USD 12.2 million (up 43.1%). FY consolidated adjusted EBITDA was USD 72.5 million (up 36.0%) and Q4 consolidated adjusted EBITDA was USD 22.4 million (up 62.5%); FY consolidated adjusted EBITDAR was USD 120.9 million (up 26.2%) and Q4 consolidated adjusted EBITDAR was USD 35.3 million (up 41.7%). In Home Health and Hospice Services, FY revenue was USD 732.7 million (up 41.0%) and Q4 revenue was USD 233.3 million (up 64.3%), with FY segment adjusted EBITDA from operations of USD 111.1 million (up 37.8%) and Q4 of USD 33.7 million (up 58.2%). FY total home health admissions were 86,076 (up 44.1%) and Q4 admissions were 28,941 (up 81.3%); FY hospice average daily census was 4,204 (up 28.6%) and Q4 was 5,060 (up 46.9%). In Senior Living Services, FY revenue was USD 215.0 million (up 22.3%) and Q4 revenue was USD 56.1 million (up 19.6%); Q4 average occupancy was 80.6% (up 200 basis points) and average monthly revenue per occupied room was USD 5,238 (up 5.6%). Pennant said 2025 included multiple acquisitions and expansion in the Southeast, and it expects to focus on integrating new operations in 2026. The company issued FY 2026 guidance for revenue of USD 1.13 billion to USD 1.17 billion, adjusted diluted EPS of USD 1.26 to USD 1.36, and adjusted EBITDA of USD 88.5 million to USD 94.1 million, including revenue of USD 191.2 million to USD 200.3 million and adjusted EBITDA of USD 16.7 million to USD 17.9 million related to former UnitedHealth and Amedisys assets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Pennant Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602251625PRIMZONEFULLFEED9661488) on February 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment